Imaging of Solid Tumors Using FAP-2286

Inclusion Criteria:

1. Age >= 18 years.

2. Histopathologically confirmed solid tumors in one of the following cohorts: a. Cohort 1 (n=11): measurable disease is not required for this cohort. i. Agnostic to tumor type. b. Cohort 2 (n=95): Metastatic disease present on conventional imaging defined ashaving RECIST 1.1 measurable disease or multiple bone metastases. Note: Presence ofabsence of metastatic disease for eligibility determination will be assessed byreviewing medical records. Screening imaging will not be conducted for this study. i. Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma,castrate-resistant prostate cancer, bladder cancer, colon cancer, or other cancertype. c. Cohort 3 (n=85): No evidence of metastatic disease as defined as the absence ofRECIST 1.1 measurable disease or bone metastases. Note: Presence of absence ofmetastatic disease for eligibility determination will be assessed by reviewingmedical records. Screening imaging will not be conducted for this study. i. Participants can be imaged at initial staging with what is judged by the treatingphysician to be high risk disease and where the presence of metastatic disease wouldgreatly impact treatment planning and prognosis. Participants may also be imagedafter therapy (surgery, chemotherapy or radiation therapy) if in the determinationof the treating physician or investigator there is a high risk of disease recurrencethat would also impact treatment plan and/or prognosis. ii. Pathologically confirmed head and neck cancer, bladder cancer, or other cancertype.

3. Ability to understand a written informed consent document, and the willingness tosign it.

Exclusion Criteria:

1. Unlikely to comply with protocol procedures, restrictions and requirements andjudged by the Investigator to be unsuitable for participation.

2. Known pregnancy.